Australia’s CSL to Buy Drugmaker Vifor for $11.7 Billion
- Offer of $179.25 a share equates to 40% premium, CSL says
- Deal extends CSL’s reach beyond flu shots and plasma
This article is for subscribers only.
Australian biotech company CSL Ltd. agreed to buy Swiss drugmaker Vifor Pharma AG for an equity value of $11.7 billion to add treatments for kidney disease and iron deficiency.
CSL is offering to buy all publicly held Vifor shares for $179.25 each -- the equivalent of 167 francs apiece. That’s a premium of 40% to the 60-day average price of the stock as of Dec. 1, CSL said Tuesday.